Prescription medication · Antihistamine (Nasal)
olopatadine nasal
Also sold as Patanase. This medicine temporarily relieves itchy and red eyes.
Data updated 2026-05-15
- $0.93
- Generic price (NADAC)
olopatadine nasal (Patanase) is a prescription Antihistamine (Nasal). This medicine temporarily relieves itchy and red eyes.
Olopatadine nasal spray is a medicine that helps with allergy symptoms. It belongs to a class of drugs called antihistamines and is used directly in the nose.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Generic Price
$0.93/unit
Generic Available
Yes (17 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
This medicine temporarily relieves itchy and red eyes.
Common side effects
No common side effects listed.
Key warnings
No specific warnings noted. Always follow your prescriber's instructions.
The sections below are summarized in plain English from olopatadine nasal's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Olopatadine is an antihistamine. It works by blocking histamine, a natural substance in your body that causes allergic symptoms. This helps to relieve itching and redness in your eyes.
How to Take It
For adults and children 2 years and older, put 1 drop in the affected eye(s) twice a day. Do this every 6 to 8 hours, but no more than twice per day. If you are using other eye products, wait at least 5 minutes between each product. Always replace the cap after each use.
This is a plain-language summary of olopatadine nasal's FDA labeling, not individualized dosing advice. Ask a pharmacist or prescriber before changing how you take this medication.
Missed Dose
If you miss a dose, use it as soon as you remember. Then, continue with your regular dosing schedule.
This is a plain-language summary of olopatadine nasal's FDA labeling, not individualized advice. Ask a pharmacist or prescriber what to do about your specific missed dose.
Common Questions
What is the right dose for me?
Can children under 2 use this?
How often can I use this?
What if I use other eye drops?
What do I do after using the drops?
What if I wear contact lenses?
Can I use this for other types of eye irritation?
What if my symptoms don't improve?
Can I use more than 1 drop at a time?
Is there a limit to how long I can use this?
What drug class is olopatadine nasal?
Related Medications in Antihistamine (Nasal)
Other drugs grouped near olopatadine nasal - same-class peers and common alternatives.
azelastine
Astelin, Astepro
Azelastine nasal spray is an antihistamine medicine.
Compare with olopatadine nasal →
budesonide nasal
Rhinocort
Rhinocort is a nasal spray that helps relieve allergy symptoms.
Compare with olopatadine nasal →
cetirizine
Zyrtec
Cetirizine (Zyrtec) is an antihistamine medicine.
Compare with olopatadine nasal →
chlorpheniramine
Chlor-Trimeton
Chlorpheniramine is an antihistamine medicine.
Compare with olopatadine nasal →
ciclesonide nasal
Omnaris, Zetonna
Omnaris Nasal Spray is a medicine that helps treat allergy symptoms in your nose.
Compare with olopatadine nasal →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
Why some drugs demand precise dosing and monitoring
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on olopatadine nasal
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for olopatadine nasal
The FDA label for olopatadine nasal (sold under brand names such as Patanase) classifies it as a prescription-only medication in the Antihistamine (Nasal) class. This medicine temporarily relieves itchy and red eyes. Labeling covers dosing, contraindications, and monitoring requirements derived from clinical trials.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. Voluntary reports accumulate over the lifetime of a drug and reflect wide-ranging clinical use. Interaction data is drawn directly from FDA-approved prescribing information. NADAC pricing from CMS shows a generic unit cost of $0.93.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice, always consult a licensed healthcare provider before starting, stopping, or changing any medication.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.
Last updated: April 14, 2025
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled and last refreshed May 2026. See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages